This trial is examining the effectiveness of Gallium-68 PSMA-11 PET imaging for determining the presence of metastatic prostate cancer. The main outcome to be measured is the detection of tumor location which will be confirmed by conventional follow-up. This study is being conducted in the UCSF Imaging Center in San Francisco, California.
The details
A biochemical recurrence of prostate cancer is generally diagnosed based on rising prostate specific antigen levels (PSA, a protein present in prostate cancer) following treatment such as surgical removal of the prostate and/or radiation. Ga-68 labelled PSMA-11 PET is a new imaging technique that may be able to determine the presence of metastatic (spread) disease. Prostate specific membrane antigen (PSMA) is a protein expressed on prostate cancer cells that can be imaged using small molecules injected before the scan that target this protein.
This trial aims to determine whether Ga-68 labelled PSMA-11 PET is effective at locating metastatic disease.
Who are they looking for?
This trial is recruiting 500 men who have a rising PSA (prostate specific antigen) after prior treatment. Participants must be able to lie flat for a period of time.
Patients should not be undergoing treatment for another cancer.
How will it work
Patients will have Gallium-68 PSMA-11 PET imaging to detect metastases. This will be confirmed using biopsy or other types of imaging, such as a CT. Patients will be followed up for 12 months.
